Amid a major restructuring and the spinoff of generics unit Sandoz, Novartis isn’t done shaking things up. The pharma giant has sold five of its …

The clock is ticking on Vanda Pharmaceuticals’ sleep disorder drug Hetlioz—and, Tuesday, it got louder. A federal court in Delaware has not only rejected Vanda’s claim …

The battle to absorb rare disease drugmaker Horizon Therapeutics will be waged with cash. That was the message from interested bidders Sanofi and Amgen, at …

As the salad days of pandemic vaccine sales wane, two mRNA camps are taking a legal stand on the global stage—and duking it out in …

Thanks to a huge end-of-year splurge, AbbVie’s immunology drug Rinvoq has retaken the top spot as having the biggest TV drug ad spend in November, …

Last month, the FDA showed it may be ready to play ball on approving nonprescription naloxone. Now, one of the overdose reversal drug’s flagship brands—Emergent …

When Eli Lilly’s Verzenio snagged an FDA go-ahead to treat certain breast cancer patients after surgery, the first-in-class nod was weakened by an unexpected limitation. …

Following a biopharma industry trend, Kyowa Kirin is narrowing its focus by offloading some mature medicines. The Japanese drugmaker will spin its international established medicines …

Thanks to a new early access deal and the intercontinental oncology effort Project Orbis, England will be the first European country where patients with later-stage …

Horizon Therapeutics has teamed up with Xeris Biopharma to create an ultra-concentrated, ready-to-use, subcutaneous formulation of teprotumumab, handing over an upfront payment and offering milestones …